Relay Therapeutics, Inc.

NASDAQ:RLAY

Biotechnology

Healthcare
$16.51 +2.63%

+$0.41 today

Market cap
$3.65B
Beta
1.75
P/E (TTM)
-10.5
EPS (TTM)
-$1.52
52W Low $3.03High $17.47

Volume 2.43M

Average 3.70M

RLAY Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Relay Therapeutics, Inc.NASDAQ: RLAY

Gross Profit · Q2 FY2026 · quarter ended Jun 2026

Gross profit turns positive

Q2 FY2026 gross profit was $350K, compared with -$60.8M a year earlier. Trailing-twelve-month gross profit was -$58.64M.

Context

  • Gross profit amounted to 76.8% of revenue in FY2025, down 2975.4 pp from a year earlier.
  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near $350K or moves back toward the trailing-twelve-month quarterly average of -$14.66M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$350K-86.0% QoQ
Last fiscal yearDec 2025
$11.8M+103.9% YoY
LTMJun 2026
-$58.64M+69.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.6%——
1 year+103.9%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
11.8M USD
Year-over-year change
+103.9%

Gross Profit vs competitors

How RLAY compares with its peers on the latest reported figures

  • RLAY's LTM Jun 2026 gross profit of -$58.64M is the lowest of the 11 companies compared; the peer median is -$229K.
  • Its year-over-year change of +69.8% is the 5th highest of 9, against a peer median of +32.6%.
  • Gross profit amounts to 566.6% of revenue for RLAY, versus a peer median of 92.1%.
RLAY Competitors Peer median
Gross Profit for RLAY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NRIXNurix Therapeutics, Inc.LTM Aug 2026$607.18M +545.5%—86.5%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$107.07M +151.2%-5.8%102.0%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$16.33M +133.3%—97.7%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 ———
TYRATyra Biosciences, Inc.LTM Mar 2026-$138K -9.5%——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026-$320K -5.3%——
TNGXTango Therapeutics, Inc.LTM Sep 2026-$942K -101.4%+34.2%—
ERASErasca, Inc.LTM Sep 2026-$1.47M -76.2%——
RVMDRevolution Medicines, Inc.LTM Jun 2026-$9.24M ———
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-$19.69M +70.5%+63.7%8.7%
RLAYRelay Therapeutics, Inc.LTM Jun 2026-$58.64M +69.8%—566.6%
Peer median (excluding RLAY) -$229K+32.6%+34.2%92.1%

Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.03M1.38M25.55M10.01M15.36M
Cost of Revenue169.39M243.01M326.39M315.44M3.56M
Gross Profit(166.36M)(241.62M)(300.84M)(305.43M)11.8M
Gross Margin-5492.2%-17496.3%-1177.6%-3052.2%76.8%
Research & Development295.65M246.36M330.02M319.09M261.38M
Selling, General & Admin59.75M69.33M78.58M80.24M56.71M
Operating Expenses198.34M57.65M72.16M67.03M314.54M
Depreciation & Amortization3.93M4.13M5.27M5.46M3.56M
EBITDA(223.08M)(306.82M)(374.15M)(380.21M)(272.92M)
EBITDA Margin-7364.9%-22217.4%-1464.6%-3799.4%-1777.4%
Operating Income(364.7M)(299.28M)(373M)(372.47M)(302.74M)
Operating Margin-12040.2%-21670.9%-1460.1%-3722.1%-1971.6%
Interest Income830K8.79M31.05M34.75M27.04M
Interest Expense00000
Other Income / Expenses826K8.77M31.03M34.76M26.26M
Income Before Tax(363.87M)(290.51M)(341.97M)(337.71M)(276.48M)
Pre-Tax Margin-12012.9%-21036.1%-1338.7%-3374.7%-1800.6%
Income Tax Expense00000
Net Income(363.87M)(290.51M)(341.97M)(337.71M)(276.48M)
Net Margin-12012.9%-21036.1%-1338.7%-3374.7%-1800.6%
EPS (Basic)(3.82)(2.59)(2.79)(2.36)(1.61)
EPS (Diluted)(3.82)(2.59)(2.79)(2.36)(1.61)
Weighted Avg Shares95.14M112.23M122.58M142.87M171.59M
Weighted Avg Shares (Diluted)95.14M112.23M122.58M142.87M171.59M

Relay Therapeutics, Inc.

NASDAQ:RLAY

Intrinsic Alpha fair value

Locked

Current Price

$16.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.